Difference between revisions of "NextGen-O2k H2020 SME Phase 1"
Line 2: | Line 2: | ||
:::: <big><big>A project in progress</big></big> | :::: <big><big>A project in progress</big></big> | ||
== | == Horizon2020 SME Instrument == | ||
[[File: | [[File:Horizon2020 logo jpg.jpg|80px|Horizon2020 logo jpg.jpg]] | ||
::::* | ::::* NextGen-O2k has successfully reached and accomplished Phase 1 of the two-step Horizon2020 SME funding instrument. | ||
::::* '''Project duration''': | ::::* '''Project duration''': 2018-02-01 to 2018-05-31. | ||
::::* Funding: '''€ 50,000'''. | |||
::::* Funding: '''€ | |||
== Project Output == | |||
The aim of the Phase 1 project was to generate a feasibility study (including a market study and a financial forecast) for the development and market launch of the NextGen-O2k and the Q2k. The freedom-to-operate (FTO) analysis that was carried out in the course of the feasibility study resulted in the following statement: | |||
"FREEDOM-TO-OPERATE: After careful analysis of these patents identified through Patent Inspiration, we | |||
conclude that we have not found any patent that overlaps with NextGen-O2k innovative properties. The | |||
combination of sensors used by us is absolutely unique and, moreover, there is no a single device that includes | |||
the Q-sensor for coenzyme Q redox state. Therefore, we have full freedom-to-operate." | |||
Revision as of 15:14, 7 August 2018
NextGen-O2k H2020 SME Phase 1
- A project in progress
Horizon2020 SME Instrument
- NextGen-O2k has successfully reached and accomplished Phase 1 of the two-step Horizon2020 SME funding instrument.
- Project duration: 2018-02-01 to 2018-05-31.
- Funding: € 50,000.
Project Output
The aim of the Phase 1 project was to generate a feasibility study (including a market study and a financial forecast) for the development and market launch of the NextGen-O2k and the Q2k. The freedom-to-operate (FTO) analysis that was carried out in the course of the feasibility study resulted in the following statement:
"FREEDOM-TO-OPERATE: After careful analysis of these patents identified through Patent Inspiration, we conclude that we have not found any patent that overlaps with NextGen-O2k innovative properties. The combination of sensors used by us is absolutely unique and, moreover, there is no a single device that includes the Q-sensor for coenzyme Q redox state. Therefore, we have full freedom-to-operate."